Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Glycotope announces licensing agreement with ONK Therapeutics for humanized GlycoBody targeting .
GlycotopeDecember 17, 2020 GMT
GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors. Berlin, Germany, December 17, 2020 - Glycotope GmbH, an oncology/immuno-oncology platform company built on world-leading glycobiology expertise, today announces that is has signed an agreement to license a humanized, tumor-specific antibody (GlycoBody) targeting an aberrantly glycosylated tumor associated form of MUC1 (TA-MUC1) to ONK Therapeutics Ltd. (ONK), an innovative natural killer (NK) cell therapy company.
ADVERTISEMENT
The GlycoBody will be integrated into ONKs pre-clinical program ONKT103, for solid tumors. ONK’s unique platform approach combines the expression of a chimeric antigen receptor (CAR) and a high affinity, membrane-bound TNF related apoptosis inducing
QuantuMDx Embarks on £11 Million Scale-up to Mass Manufacture its Diagnostic Q-POC™ Device and Disposable Test Cassette koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.
Sequana Medical NV: Sequana Medical announces January 2021 Investor Conference Schedule
-
Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference.
10
, 6-8 and 11-14 January 2021
H.C. Wainwright Bioconnect 2021
, 11-14 January 2021
The company presentation with webcast by Ian Crosbie, CEO, will be available on demand as of 11 January 2021 on the Conference website and on the Sequana Medical
Investors website.
To request a one-on-one meeting with Sequana Medical management at one of these events, contact us at
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
DUBLIN, Ireland, and Boston MA, December 17, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce Ministry of Health reimbursement approval has been granted for Lojuxta® (lomitapide) in the Kingdom of Saudi Arabia.
Lojuxta® has been approved as an adjunct to a low-fat diet and other lipid-lowering treatments, with or without low density lipoprotein (LDL) apheresis, to reduce low-density lipoprotein cholesterol (LDL-C) in adult patients with homozygous familial hypercholesterolaemia (HoFH).
Sequana Medical is a commercial stage medical device company developing the
alfapump platform for the management of fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. Fluid overload is a fast growing complication of advanced liver disease driven by NASH (non-alcoholic steatohepatitis) related cirrhosis and a common complication in heart failure. The U.S. market for the
alfapump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years. The heart failure market for the
alfapump DSR (Direct Sodium Removal) is estimated to be over €5 billion annually in the U.S. and EU5 by 2026. Both indications leverage Sequana Medical s